串联⁹⁰Y/¹⁷⁷Lu-DOTA-TATE肽受体放射性配体治疗神经内分泌肿瘤的20年长期毒性:波兰多中心真实世界研究
该回顾性多中心研究纳入2002至2016年间接受串联[⁹⁰Y]Y/[¹⁷⁷Lu]Lu-DOTA-TATE治疗的89例神经内分泌肿瘤患者,随访9–20年评估长期肾、血液及肝脏毒性。结果显示≥3级肾毒性仅3.4%,中位eGFR年下降2.1 mL/min/1.73 m²,10年CKD累积发生率达51%,但无终末期肾病;≥3级血小板减少5.6%,1例MDS发生于超标准累积活度后,重复治疗未见显著额外毒性。
要点
- 串联RLT后≥3级肾毒性与血小板减少发生率低,分别为3.4%与5.6%。
- 随访中位eGFR年下降2.1 mL/min/1.73 m²,10年CKD累积发生率达51%。
- 重复串联RLT未检出显著额外长期肾或血液毒性。
核心结论
- 串联RLT与低严重晚期毒性相关,但肾功能逐渐长期下降常见。
- 长期真实世界数据支持在筛选的NET患者中串联RLT的长期可行性。
研究设计与样本
- 回顾性多中心研究,纳入2002–2016年接受串联[⁹⁰Y]Y/[¹⁷⁷Lu]Lu-DOTA-TATE治疗的89例NET患者,随访9–20年。
- 评估长期肾、血液和肝脏毒性,并采用患者水平年eGFR下降及CKD时间到事件分析。
主要发现
- ≥3级肾毒性发生率为3.4%。
- 中位年eGFR下降为-2.1 mL/min/1.73 m²,合并肾毒性者下降更陡(-4.2 vs -1.6 mL/min/1.73 m²/年;p<0.001)。
- 10年CKD累积发生率达51%,未观察到需透析或移植的终末期肾病。
- ≥3级血小板减少发生率为5.6%,1例骨髓增生异常综合征发生于超标准累积活度后。
- 重复串联RLT者(16.9%)未检出统计学显著的额外长期肾或血液毒性。
关键数值与推荐
- ≥3级肾毒性3.4%,≥3级血小板减少5.6%。
- 中位年eGFR下降-2.1 mL/min/1.73 m²;肾毒性组-4.2 vs 无肾毒性组-1.6 mL/min/1.73 m²/年(p<0.001)。
- 10年CKD累积发生率51%;无终末期肾病需透析或移植病例。
- 重复串联RLT者占16.9%,未检出显著额外长期肾或血液毒性。
临床怎么用
- 对接受串联RLT的NET患者应长期纵向监测肾功能(如年eGFR变化)及血液学指标。
- 重复串联RLT在筛选患者中未显示显著额外长期毒性,但仍需个体化评估。
局限性
- 回顾性研究设计。
- 单国多中心真实世界队列,样本量89例。
- 原文未报告对照组或前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radioligand therapy (RLT) targeting somatostatin receptors is an established treatment for advanced neuroendocrine tumors (NETs). While long-term safety data for [¹⁷⁷Lu]Lu-DOTA-TATE monotherapy are increasingly available, evidence regarding late toxicity of tandem RLT combining ⁹⁰Y- and ¹⁷⁷Lu-labeled somatostatin analogues remains limited. We evaluated the long-term safety profile of tandem [⁹⁰Y]Y/[¹⁷⁷Lu]Lu-DOTA-TATE RLT in a large real-world cohort with extended follow-up. METHODS: This retrospective study included 89 patients with NETs treated between 2002 and 2016 and followed for 9-20 years. Long-term renal, hematological, and hepatic toxicities were assessed. Renal function was analyzed longitudinally using patient-level annual estimated eGFR decline and time-to-event analysis for chronic kidney disease (CKD). Patients undergoing repeated RLT were analyzed separately. RESULTS: Grade ≥ 3 nephrotoxicity was observed in 3.4%. Median annual eGFR decline was - 2.1 mL/min/1.73 m² and was significantly steeper in patients with nephrotoxicity (- 4.2 vs. -1.6 mL/min/1.73 m²/year; p < 0.001). The cumulative incidence of CKD reached 51% at 10 years, while no cases of end-stage renal disease requiring dialysis or transplantation were observed. Grade ≥ 3 thrombocytopenia occurred in 5.6%, and one case of myelodysplastic syndrome was observed after supra-standard cumulative activity. Among patients undergoing repeated tandem RLT (16.9%), no statistically significant excess long-term renal or hematological toxicity was detected. CONCLUSION: Tandem RLT was associated with low rates of severe late toxicity, even after very prolonged follow-up and repeated treatment courses, although gradual long-term decline in renal function was common. These data provide a rare long-term real-world benchmark for late toxicity of high-energy β-emitter-based RLT and support the long-term feasibility of tandem RLT in selected patients with NETs.
引用
- Kołodziej M, Zemczak A, Pełka K, et al. Long-term toxicity of tandem radioligand therapy using [90Y]Y/[177Lu]Lu-DOTA-TATE in neuroendocrine tumors: a polish multicenter experience with 20-year follow-up. Eur J Nucl Med Mol Imaging. 2026. PMID: 42234004. doi:10.1007/s00259-026-07941-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。